Premier Inc is a healthcare improvement company that collaborates with a vast network of hospitals and healthcare systems to enhance the quality and efficiency of patient care
It provides a range of services, including data analytics, supply chain solutions, and clinical best practices, aimed at driving better health outcomes while reducing costs. By leveraging its robust connectivity and resources, Premier supports its members in navigating the complexities of the healthcare landscape, ultimately striving to transform the delivery and management of healthcare services across the country.
Over the past six months, Premier’s shares (currently trading at $17.93) have posted a disappointing 13.5% loss, well below the S&P 500’s 6.2% gain. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
Shares of healthcare tech company Premier (NASDAQPINC)
fell 14.3% in the afternoon session after the company reported weak fourth-quarter results, with its revenue and EPS falling short of Wall Street's estimates. Sales declined year on year, partly, reflecting the exit from the S2S Global direct sourcing business. And although it raised its full-year EPS forecast, its EBITDA guidance (more important) missed. Overall, this was a weaker quarter.
Healthcare tech company Premier (NASDAQPINC) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 28.2% year on year to $240.3 million. The company’s full-year revenue guidance of $975 million at the midpoint came in 1.6% below analysts’ estimates. Its non-GAAP profit of $0.25 per share was 16% below analysts’ consensus estimates.
U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies.
FTC probes chemotherapy shortages, scrutinizing drug distributors and hospital groups. Root causes of drug shortages under scrutiny. Industry defends practices.
